International and cross-cultural research is critical for understanding multilevel influences on health, health behaviors, and disease. A particularly relevant area of need for such research is tobacco control. The tobacco epidemic is one of the biggest public health threats globally, killing over 7 million people a year. Research critical to addressing this public health problem has leveraged variability in tobacco use, history, product market, and policies across different countries, settings, and populations, particularly in low- and middle-income countries (LMICs) where the tobacco burden is increasing. These efforts are needed in order to advance the science and inform practice and policy in various settings, including the US. Several funding agencies provide support for international research focused on tobacco control in LMICs because of the importance and implications of such research. This paper provides some concrete examples of how such research has advanced our knowledge-base and informed practice and policy globally, particularly in high-income countries including the US. Some prominent themes emphasized in this manuscript include: the development of knowledge regarding the diverse tobacco products on the market; better understanding of tobacco use and its impact among different populations; generating knowledge about the impacts including unintended consequences of tobacco control policy interventions; and better understanding tobacco industry strategies and informing advocacy efforts. In summary, international tobacco control research, particularly in LMICs, is critical in effectively and efficiently building the evidence base to advance tobacco control research, policy, and practice globally, including the US, with the ultimate goal of curbing the tobacco epidemic.
Bibliographical noteFunding Information:
This publication was supported by the following funding sources: Carla J Berg receives funding from the US Fogarty International Center/National Cancer Institute (1R01 TW010664-01). Geoffrey T Fong was supported by grants from the US National Cancer Institute (P01 CA200512), the Canadian Institutes of Health Research (FDN-148477), and a Senior Investigator grant from the Ontario Institute for Cancer Research. James F Thrasher receives funding from the US Fogarty International Center/National Cancer Institute (R01 TW009274 and R01 TW010652) and US National Cancer Institute (R01 CA167067). Joanna Cohen is supported by a grant from Bloomberg Philanthropies as part of the Bloomberg Initiative to Reduce Tobacco Use. Wasim Maziak is supported by the US National Institute on Drug Abuse (R01DA035160), US Fogarty International Center (R01TW010654), and U54MD012393-01 for the FIU-RCMI. Harry Lando received funding from the US Fogarty International Center (R01 TW005969 and R56TW009265). Jeffrey Drope receives funds from the Fogarty International Center, National Cancer Institute, and Office of Behavioral and Social Sciences Research (R01 TW010898). Raul Mejia receives funding from the Global Health Leadership Award from the International Development Research Centre, Canada, as well as the US Fogarty International Center/National Cancer Institute (R01 TW009274). Joaquin Barnoya receives support from the Foundation for Barnes-Jewish Hospital. Rima Nakkash receives funding from the International Development Research Centre, Canada. Ramzi Salloum receives funding from the International Development Research Centre, Canada.
© 2018 Elsevier Ltd
- Global tobacco
- Research capacity-building
- Tobacco control